肥胖与癌症：血管生成与炎症之间的联系
Obesity and Cancer: An Angiogenic and Inflammatory Link.
作者信息
Fukumura Dai, Incio Joao, Shankaraiah Ram C, Jain Rakesh K
机构信息
Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
I3S, Institute for Innovation and Research in Heath, Metabolism, Nutrition and Endocrinology Group, Biochemistry Department, Faculty of Medicine, Porto University, Porto, Portugal.
出版信息
Microcirculation. 2016 Apr;23(3):191-206. doi: 10.1111/micc.12270.
With the current epidemic of obesity, a large number of patients diagnosed with cancer are overweight or obese. Importantly, this excess body weight is associated with tumor progression and poor prognosis. The mechanisms for this worse outcome, however, remain poorly understood. We review here the epidemiological evidence for the association between obesity and cancer, and discuss potential mechanisms focusing on angiogenesis and inflammation. In particular, we will discuss how the dysfunctional angiogenesis and inflammation occurring in adipose tissue in obesity may promote tumor progression, resistance to chemotherapy, and targeted therapies such as anti-angiogenic and immune therapies. Better understanding of how obesity fuels tumor progression and therapy resistance is essential to improve the current standard of care and the clinical outcome of cancer patients. To this end, we will discuss how an anti-diabetic drug such as metformin can overcome these adverse effects of obesity on the progression and treatment resistance of tumors.
随着当前肥胖症的流行，大量被诊断患有癌症的患者超重或肥胖。重要的是，这种超重与肿瘤进展和预后不良有关。然而，这种较差结果的机制仍知之甚少。我们在此回顾肥胖与癌症之间关联的流行病学证据，并讨论以血管生成和炎症为重点的潜在机制。特别是，我们将讨论肥胖时脂肪组织中发生的功能失调的血管生成和炎症如何促进肿瘤进展、对化疗的耐药性以及抗血管生成和免疫治疗等靶向治疗。更好地理解肥胖如何助长肿瘤进展和治疗耐药性对于提高当前的护理标准和癌症患者的临床结局至关重要。为此，我们将讨论二甲双胍等抗糖尿病药物如何克服肥胖对肿瘤进展和治疗耐药性的这些不利影响。
Zotero 插件